
    
The genomic variant c.3733C>T p.Arg1245Ter rs727504136 in the SCN1A gene is a pathogenic mutation characterized by the substitution of a cytosine for a thymine at nucleotide position 3733, which results in the introduction of a premature stop codon at arginine 1245 (p.Arg1245Ter). This variant has been associated with Dravet syndrome (DS), a severe form of epilepsy with onset in infancy that includes febrile seizures and a spectrum of other seizure types leading to neurodevelopmental delays [2][5][6]. The variant has been classified as pathogenic according to the American College of Medical Genetics and Genomics (ACMG) criteria, which includes very strong evidence of pathogenicity (PVS1), strong evidence (PS4_Mod), and moderate evidence (PM2_SUP) [2]. This classification is supported by the observation that the variant has been reported in multiple unrelated individuals with Dravet syndrome and is absent from controls [2][5].The SCN1A gene encodes the alpha subunit of the neuronal voltage-gated sodium channel Na_v1.1, which is critical for the initiation and propagation of action potentials in neurons. Mutations in SCN1A can lead to altered channel function, affecting the excitability of neurons and resulting in the clinical manifestations of epilepsy and related neurodevelopmental disorders.The c.3733C>T variant has been reported in several patients with Dravet syndrome, presenting with early-onset febrile seizures and a range of other seizure types, as well as developmental delays and, in some cases, features of autism [5][6]. The variant has been identified as de novo in multiple cases, which is consistent with the typical inheritance pattern of Dravet syndrome where most cases are sporadic due to de novo mutations [5][6].Furthermore, the c.3733C>T variant has been implicated in cases with co-morbid mitochondrial disease, where patients exhibited defects in mitochondrial electron transport chain complex activity alongside the clinical features of Dravet syndrome [6]. This suggests a potential overlap in the pathophysiological mechanisms of mitochondrial dysfunction and sodium channelopathy in these patients.In summary, the c.3733C>T p.Arg1245Ter rs727504136 variant in the SCN1A gene is a pathogenic stop-gained mutation associated with Dravet syndrome, characterized by early-onset febrile seizures, a spectrum of other seizure types, and developmental delays. The mutation results in a truncated protein product, likely leading to loss of function of the Na_v1.1 channel, which plays a crucial role in neuronal excitability and the pathogenesis of epilepsy.

SCN1A遺伝子におけるゲノム変異c.3733C>T p.Arg1245Ter rs727504136は、病原性のある変異であり、ヌクレオチド位置3733でシトシンがチミンに置換されることで、アルギニン1245（p.Arg1245Ter）における早期終止コドンが導入されることが特徴です。この変異は、乳児期に発症する重度のてんかんであるドラベ症候群（DS）と関連しており、発熱性けいれんやその他のさまざまなけいれん型を含み、神経発達の遅れを引き起こします[2][5][6]。この変異は、アメリカ医療遺伝学・ゲノム学会（ACMG）の基準に基づき、病原性があると分類されており、非常に強い病原性の証拠（PVS1）、強い証拠（PS4_Mod）、および中程度の証拠（PM2_SUP）が含まれています[2]。この分類は、ドラベ症候群の複数の無関係な患者でこの変異が報告されており、対照群では見られないことによって支持されています[2][5]。

SCN1A遺伝子は、神経電位依存性ナトリウムチャネルNa_v1.1のαサブユニットをコードしており、ニューロンにおける活動電位の開始と伝播に重要な役割を果たします。SCN1Aの変異はチャネル機能の変化を引き起こし、ニューロンの興奮性に影響を与え、てんかんや関連する神経発達障害の臨床症状をもたらす可能性があります。

c.3733C>T変異は、早期発症の発熱性けいれんやその他のさまざまなけいれん型、発達遅延、場合によっては自閉症の特徴を伴うドラベ症候群の患者で報告されています[5][6]。この変異は複数の症例でde novo（新生変異）として確認されており、ドラベ症候群の典型的な遺伝パターンである、ほとんどの症例が新生変異による散発的なものであることと一致しています[5][6]。

さらに、c.3733C>T変異は、ミトコンドリア疾患を併発した症例でも関与しており、これらの患者はドラベ症候群の臨床的特徴に加えて、ミトコンドリア電子伝達系複合体活性の欠陥を示しました[6]。これは、ミトコンドリア機能障害とナトリウムチャネル障害の病態生理学的メカニズムの重なりの可能性を示唆しています。

まとめると、SCN1A遺伝子におけるc.3733C>T p.Arg1245Ter rs727504136変異は、ドラベ症候群と関連する病原性のある終止コドン変異であり、早期発症の発熱性けいれん、さまざまなけいれん型、および発達遅延を特徴としています。この変異は、Na_v1.1チャネルの機能喪失を引き起こす可能性が高いタンパク質の切断をもたらし、ニューロンの興奮性およびてんかんの病因に重要な役割を果たします。
    
## References
- [1] Viswanathan LGet al. (2023). "Phenotypic features of epilepsy due to sodium channelopathies - A single center experience from India." Journal of neurosciences in rural practice, 14(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38059254/)
- [2] Ademuwagun IA et al. (2025). "Exome sequencing in Nigerian children with early-onset epilepsy syndromes." Epilepsia open, 10(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/39570184/)
- [3] Cho MJ et al. (2018). "Efficacy of Stiripentol in Dravet Syndrome with or without SCN1A Mutations." Journal of clinical neurology (Seoul, Korea), 14(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/29141279/)
- [4] Xu X et al. (2015). "Amplicon Resequencing Identified Parental Mosaicism for Approximately 10% of "de novo" SCN1A Mutations in Children with Dravet Syndrome." Human mutation, 36(9) [PubMed](https://pubmed.ncbi.nlm.nih.gov/26096185/)
- [5] Zhang Y et al. (2015). "Gene Mutation Analysis in 253 Chinese Children with Unexplained Epilepsy and Intellectual/Developmental Disabilities." PloS one, 10(11) [PubMed](https://pubmed.ncbi.nlm.nih.gov/26544041/)
- [6] Craig AK et al. (2012). "Dravet syndrome: patients with co-morbid SCN1A gene mutations and mitochondrial electron transport chain defects." Seizure, 21(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/21906962/)
- [7] Yang X et al. (2017). "Genomic mosaicism in paternal sperm and multiple parental tissues in a Dravet syndrome cohort." Scientific reports, 7(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/29142202/)
- [8] Dorota Hoffman Zacharskaa et al. (2016). "Can the p.Thr1174Ser Mutation in SCN1A Gene Shape Genetic Background inEpileptic Encephalopathies" Journal of Genetic Syndromes & Gene Therapy, 7 [PubMed](https://doi.org/10.4172/2157-7412.1000290)
- [9] X. Tian et al. (2016). "Phenotype and gene mutation screening in familial Dravet syndrome" Chinese Journal of Applied Clinical Pediatrics, 31 [PubMed](https://doi.org/10.3760/CMA.J.ISSN.2095-428X.2016.20.003)
- [10] Zhang L et al. (2015). "Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma." American journal of human genetics, 96(4) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/25839328/)
- [11] Yang L et al. (2024). "Phase separation as a possible mechanism for dosage sensitivity." Genome biology, 25(1) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/38225666/)
- [12] Cheng C et al. (2016). "Genomic analyses reveal FAM84B and the NOTCH pathway are associated with the progression of esophageal squamous cell carcinoma." GigaScience, 5() [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/26759717/)
- [13] Du P et al. (2017). "Comprehensive genomic analysis of Oesophageal Squamous Cell Carcinoma reveals clinical relevance." Scientific reports, 7(1) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/29127303/)
- [14] Yang S et al. (2017). "Sources of discordance among germ-line variant classifications in ClinVar." Genetics in medicine : official journal of the American College of Medical Genetics, 19(10) [SUPP] [PubMed](https://pubmed.ncbi.nlm.nih.gov/28569743/)

    
## ClinVar Submissions
- **[RCV000153888](https://www.ncbi.nlm.nih.gov/clinvar/RCV000153888/)**: Severe myoclonic epilepsy in infancy
- **[RCV000188925](https://www.ncbi.nlm.nih.gov/clinvar/RCV000188925/)**: not provided
- **[RCV001040173](https://www.ncbi.nlm.nih.gov/clinvar/RCV001040173/)**: Early infantile epileptic encephalopathy with suppression bursts
- **[RCV002316972](https://www.ncbi.nlm.nih.gov/clinvar/RCV002316972/)**: Inborn genetic diseases
- **[RCV002492580](https://www.ncbi.nlm.nih.gov/clinvar/RCV002492580/)**: Migraine, familial hemiplegic, 3 (and 3 more)

    